June 4-8, 2021; Online at https://conferences.asco.org/am
Early-stage results with ivosidenib and venetoclax with or without azacitidine suggest a high CRc with a tolerable safety profile in patients with IDH1-mutated myeloid malignancies
Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191
Supported by educational grants from
AbbVie
AstraZeneca
Bristol-Myers Squibb
GlaxoSmithKline
Novartis Pharmaceuticals Corporation
Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc.
Sanofi Genzyme
Leaving the CCO site
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.